Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$$$ UNVC $$$
Naysayers, Flippers, Marketmakers steal wealth by fear impatience and deceit. Everyday trying to create panic. The float will dry up . PR will make new beginnings. Univec Conglomerate Inc. Book it
— Dr. David Dalton (@DrDavidDalton1) June 28, 2019
Check Dr. Dalton’s Twitter page now.
Black Enterprise BE100
Connect the Dot
Black Enterprise BE100
— Dr. David Dalton (@DrDavidDalton1) June 29, 2019
Connect the Dot
Per Dr. D himself:
“The float will dry up . PR will make new beginnings. Univec Conglomerate Inc. Book it”- Univec Conglomerate CEO Dr. David Dalton
Naysayers, Flippers, Marketmakers steal wealth by fear impatience and deceit. Everyday trying to create panic. The float will dry up . PR will make new beginnings. Univec Conglomerate Inc. Book it
— Dr. David Dalton (@DrDavidDalton1) June 28, 2019
The following really has me intrigued. Read through it and you will see UNVC CEO in it. I even provide links:
$$$ Univec Conglomerate/UNVC$$$
https://twitter.com/shortsleaves/status/1139131208183549952?s=21
$$$ UNVC $$$ The following was posted on SEDAR.You will see CEO Dr. David Dalton as well as UNVC referenced in it. This is part of the Univec Conglomerate.
https://sedar.com/CheckCode.do
REWARDSTREAM ENTERS INTO DEFINITIVE AGREEMENT TO ACQUIRE INTEREST IN ISRAELI CANNABIS LICENSEE
Vancouver, British Columbia, June 12, 2019 – RewardStream Solutions Inc. (TSXV: REW and Frankfurt: JL4L, WKN Number A2APX1) (the “Company”) is pleased to announce it has entered into a definitive share purchase agreement (the “Definitive Agreement”), dated effective June 11, 2019, with EuroMed Therapeutics Ltd. (“EuroMed”) and its shareholders. EuroMed is an arms’-length company, established under the laws of the Province of British Columbia, for the purpose of cultivation and exporting of medical grade cannabis produced in greenhouse facilities located in Israel. EuroMed aims to be a leading low-cost high-quality medical grade cannabis producer in Israel with a focus on both the domestic Israeli market and the emerging European cannabis market. The Definitive Agreement replaces the existing letter of intent entered into with EuroMed and dated effective April 30, 2019.
EuroMed, through its participation in a joint venture, will embark on an industrial-scale cannabis farming operation including up to a 269,098 square foot (25 dunam) cannabis designated cultivation property located 45 minutes outside of Jerusalem, Israel. The venture intends to build a 22,000 square feet greenhouse facility on the property to cultivate medical grade cannabis for the purposes of servicing the domestic medical cannabis market and exports into Europe. EuroMed will be working with leading greenhouse engineering and construction firm Eisenberg Agri Company (Israel) Limited (EACi) to design and build a state-of-the-art modular greenhouse facility with expected completion by March 2020.
Further Details Regarding the Transaction
Pursuant to the Definitive Agreement, the Company proposes to acquire all of the outstanding share capital of EuroMed (the “Transaction”). In accordance with the terms of the Transaction, the Company proposes to consolidate its outstanding share capital (the “Share Consolidation”) on a two-for-one basis, and issue 40,000,000 post-Share Consolidation common shares (the “Consideration Shares”) to the shareholders of EuroMed in exchange for all of the outstanding share capital of EuroMed.
Prior to closing of the Transaction, the Company intends to apply to list its common shares on the Canadian Securities Exchange, and voluntarily delist its shares from the TSX Venture Exchange. On closing of the Transaction, it is anticipated that the Company will change its name to “EuroMed Therapeutics Ltd.”
In connection with the Transaction, the Company anticipates issuing 4,500,000 post-Share Consolidation common shares to an arms’-length third party who assisted in introducing the Transaction to the Company.
It is a condition to completion of the Transaction that the Company undertake a non-brokered private placement (the “Financing”) of subscription receipts (each, a “Receipt”) to raise not less than $2,500,000. In order to satisfy this condition, the Company intends to offer up to 5,000,000 Receipts, at a price of $0.50 per Receipt. Proceeds of the Financing will be held in escrow pending completion of the Transaction. Immediately prior to completion of the Transaction, each Receipt will automatically be converted into one unit of the Company (each, a “Receipt Unit”). Each “Receipt Unit” will consist of one post-Share Consolidation common share of the Company, and one-half-of- one share purchase warrant (each whole warrant, a “Receipt Warrant”). Each “Receipt Warrant” will entitle the holder to acquire an additional post-Share Consolidation common share at a price of $1.00 for a period of twenty-four months from their date of issue.
All securities issued in connection with the Financing, as well as the securities issued as compensation for introducing the Transaction, will be subject to a four-month-and-one-day statutory hold period.
Completion of the Transaction remains subject to a number of conditions, including receipt of any required regulatory and third-party consents, approval of minority shareholders of the Company to the delisting of the Company’s common shares from the TSX Venture Exchange, completion of the Share Consolidation, completion of the Financing, the Canadian Securities Exchange having conditionally accepted the listing of the Company’s common shares, the TSX
Venture Exchange having consented to the voluntarily delisting of the Company’s common shares, and the satisfaction of other customary closing conditions.
The Transaction cannot close until the required approvals are obtained, and the Company’s common shares have been delisted from the TSX Venture Exchange. There can be no assurance that the Transaction will be completed as proposed or at all, or that the Company’s common shares will be listed and posted for trading on any stock exchange. Trading in the Company’s common shares is currently suspended and it is anticipated that trading will remain suspended until completion of the Transaction.
Proposed Management and Board of Directors of the Resulting Issuer
Following completion of the Transaction, it is anticipated that the board of directors of the Company will be reconstituted to consist of Patrick Morris, Geoff Balderson, David Dalton and one additional nominee to be agreed between the Company and EuroMed. Management of the Company will consist of Patrick Morris as Chief Executive Officer and Corporate Secretary, and Geoff Balderson as Chief Financial Officer. The following are brief profiles of the proposed members of management and the board of directors:
Patrick Morris: Director, Chief Executive Officer and Corporate Secretary
Mr. Morris is an entrepreneur and capital markets executive experienced in a number of industries including resource exploration, pharmaceutical cannabis, blockchain technologies, and finance. With 15 years of capital markets experience raising funds for microcap companies and executing corporate development strategies, Mr. Morris has taken numerous companies public through initial public offerings and reverse takeover transactions. Mr. Morris also co-created and co-produced Canada’s first nationally syndicated radio show about growth stock opportunities broadcast on fourteen of the top-rated news talk stations across Canada.
Geoff Balderson: Director and Chief Financial Officer
Mr. Balderson is the President of Flow Capital Corp. and Harmony Corporate Services Ltd., both private business consulting companies located in Vancouver, British Columbia. Mr. Balderson has been an officer and director of several TSX Venture Exchange listed companies over the past 12 years. Prior to that he was an investment advisor at Union Securities and Georgia Pacific Securities Corp.
David Dalton: Independent Director
Dr. Dalton is a director of AGRIMED, which owns one of the twelve licenses authorized by the Commonwealth of Pennsylvania to grow and process medical cannabis. In addition to over 45 years’ experience in the pharmaceutical world, Dr. Dalton served over 18 years as Vice President of Rite Aid, a chain of retail drug stores, and then founded and served as Chairman, President, CEO of several successful pharmaceutical and pharmaceutical related companies: Mednet, ManagedcareRx, Sivault Systems. Dr. Dalton is presently Chairman, President, CEO of Wellness Teladoc, Pharmacy Services Inc, Health Resources Inc and Univec Inc (UNVC). Dr. Dalton is an inductee of three Halls of Fame, has received recognition from several presidents of the United States, and is a recipient of the Senatorial-Medal of Freedom. Dr. Dalton received a Doctor of Pharmacy from West Virginia University School of Pharmacy. In addition to his extensive background in pharmaceutical field, he is a visiting professor and lectures at several schools of pharmacy throughout the United States, and former President of West Virginia University School of Pharmacy Presidential Committee.
Further information regarding the Transaction, including a detailed use of proceeds for the Financing and financial information of EuroMed, will be made available in due course. Readers are encouraged to review the listing statement which will be prepared by the Company in connection with the listing of the Company on the Canadian Securities Exchange, and which will be made available under the Company’s profile on SEDAR (www.sedar.com).
$$$ UNVC $$$
Just a reminder for new eyes since we are very high on the bb:
“PPSI subsidiary of Univec Conglomerate Inc. (UNVC) will have patient assistance , access , a change is on it’s way.”- Dalton
https://www.linkedin.com/feed/update/urn:li:activity:6550158965915951104?commentUrn=urn%3Ali%3Acomment%3A%28activity%3A6550158965915951104%2C6550206489519276033%29
UNVC has a great looking chart.
$$$ UNVC $$$
You will do just fine. You will be set.
$$$ UNVC $$$
UNVC Univec Conglomerate is going to be like investing in a major IPO.
$$$ UNVC $$$
That is huge Mikey. UNVC is going to be one for the record books.
$$$ UNVC $$$
“The float will dry up . PR will make new beginnings. Univec Conglomerate Inc. Book it”- Univec Conglomerate CEO Dr. David Dalton
Naysayers, Flippers, Marketmakers steal wealth by fear impatience and deceit. Everyday trying to create panic. The float will dry up . PR will make new beginnings. Univec Conglomerate Inc. Book it
— Dr. David Dalton (@DrDavidDalton1) June 28, 2019
$$$ Univec Conglomerate/UNVC$$$
https://twitter.com/shortsleaves/status/1139131208183549952?s=21
$$$ UNVC $$$ The following was posted on SEDAR.You will see CEO Dr. David Dalton as well as UNVC referenced in it. This is part of the Univec Conglomerate.
https://sedar.com/CheckCode.do
REWARDSTREAM ENTERS INTO DEFINITIVE AGREEMENT TO ACQUIRE INTEREST IN ISRAELI CANNABIS LICENSEE
Vancouver, British Columbia, June 12, 2019 – RewardStream Solutions Inc. (TSXV: REW and Frankfurt: JL4L, WKN Number A2APX1) (the “Company”) is pleased to announce it has entered into a definitive share purchase agreement (the “Definitive Agreement”), dated effective June 11, 2019, with EuroMed Therapeutics Ltd. (“EuroMed”) and its shareholders. EuroMed is an arms’-length company, established under the laws of the Province of British Columbia, for the purpose of cultivation and exporting of medical grade cannabis produced in greenhouse facilities located in Israel. EuroMed aims to be a leading low-cost high-quality medical grade cannabis producer in Israel with a focus on both the domestic Israeli market and the emerging European cannabis market. The Definitive Agreement replaces the existing letter of intent entered into with EuroMed and dated effective April 30, 2019.
EuroMed, through its participation in a joint venture, will embark on an industrial-scale cannabis farming operation including up to a 269,098 square foot (25 dunam) cannabis designated cultivation property located 45 minutes outside of Jerusalem, Israel. The venture intends to build a 22,000 square feet greenhouse facility on the property to cultivate medical grade cannabis for the purposes of servicing the domestic medical cannabis market and exports into Europe. EuroMed will be working with leading greenhouse engineering and construction firm Eisenberg Agri Company (Israel) Limited (EACi) to design and build a state-of-the-art modular greenhouse facility with expected completion by March 2020.
Further Details Regarding the Transaction
Pursuant to the Definitive Agreement, the Company proposes to acquire all of the outstanding share capital of EuroMed (the “Transaction”). In accordance with the terms of the Transaction, the Company proposes to consolidate its outstanding share capital (the “Share Consolidation”) on a two-for-one basis, and issue 40,000,000 post-Share Consolidation common shares (the “Consideration Shares”) to the shareholders of EuroMed in exchange for all of the outstanding share capital of EuroMed.
Prior to closing of the Transaction, the Company intends to apply to list its common shares on the Canadian Securities Exchange, and voluntarily delist its shares from the TSX Venture Exchange. On closing of the Transaction, it is anticipated that the Company will change its name to “EuroMed Therapeutics Ltd.”
In connection with the Transaction, the Company anticipates issuing 4,500,000 post-Share Consolidation common shares to an arms’-length third party who assisted in introducing the Transaction to the Company.
It is a condition to completion of the Transaction that the Company undertake a non-brokered private placement (the “Financing”) of subscription receipts (each, a “Receipt”) to raise not less than $2,500,000. In order to satisfy this condition, the Company intends to offer up to 5,000,000 Receipts, at a price of $0.50 per Receipt. Proceeds of the Financing will be held in escrow pending completion of the Transaction. Immediately prior to completion of the Transaction, each Receipt will automatically be converted into one unit of the Company (each, a “Receipt Unit”). Each “Receipt Unit” will consist of one post-Share Consolidation common share of the Company, and one-half-of- one share purchase warrant (each whole warrant, a “Receipt Warrant”). Each “Receipt Warrant” will entitle the holder to acquire an additional post-Share Consolidation common share at a price of $1.00 for a period of twenty-four months from their date of issue.
All securities issued in connection with the Financing, as well as the securities issued as compensation for introducing the Transaction, will be subject to a four-month-and-one-day statutory hold period.
Completion of the Transaction remains subject to a number of conditions, including receipt of any required regulatory and third-party consents, approval of minority shareholders of the Company to the delisting of the Company’s common shares from the TSX Venture Exchange, completion of the Share Consolidation, completion of the Financing, the Canadian Securities Exchange having conditionally accepted the listing of the Company’s common shares, the TSX
Venture Exchange having consented to the voluntarily delisting of the Company’s common shares, and the satisfaction of other customary closing conditions.
The Transaction cannot close until the required approvals are obtained, and the Company’s common shares have been delisted from the TSX Venture Exchange. There can be no assurance that the Transaction will be completed as proposed or at all, or that the Company’s common shares will be listed and posted for trading on any stock exchange. Trading in the Company’s common shares is currently suspended and it is anticipated that trading will remain suspended until completion of the Transaction.
Proposed Management and Board of Directors of the Resulting Issuer
Following completion of the Transaction, it is anticipated that the board of directors of the Company will be reconstituted to consist of Patrick Morris, Geoff Balderson, David Dalton and one additional nominee to be agreed between the Company and EuroMed. Management of the Company will consist of Patrick Morris as Chief Executive Officer and Corporate Secretary, and Geoff Balderson as Chief Financial Officer. The following are brief profiles of the proposed members of management and the board of directors:
Patrick Morris: Director, Chief Executive Officer and Corporate Secretary
Mr. Morris is an entrepreneur and capital markets executive experienced in a number of industries including resource exploration, pharmaceutical cannabis, blockchain technologies, and finance. With 15 years of capital markets experience raising funds for microcap companies and executing corporate development strategies, Mr. Morris has taken numerous companies public through initial public offerings and reverse takeover transactions. Mr. Morris also co-created and co-produced Canada’s first nationally syndicated radio show about growth stock opportunities broadcast on fourteen of the top-rated news talk stations across Canada.
Geoff Balderson: Director and Chief Financial Officer
Mr. Balderson is the President of Flow Capital Corp. and Harmony Corporate Services Ltd., both private business consulting companies located in Vancouver, British Columbia. Mr. Balderson has been an officer and director of several TSX Venture Exchange listed companies over the past 12 years. Prior to that he was an investment advisor at Union Securities and Georgia Pacific Securities Corp.
David Dalton: Independent Director
Dr. Dalton is a director of AGRIMED, which owns one of the twelve licenses authorized by the Commonwealth of Pennsylvania to grow and process medical cannabis. In addition to over 45 years’ experience in the pharmaceutical world, Dr. Dalton served over 18 years as Vice President of Rite Aid, a chain of retail drug stores, and then founded and served as Chairman, President, CEO of several successful pharmaceutical and pharmaceutical related companies: Mednet, ManagedcareRx, Sivault Systems. Dr. Dalton is presently Chairman, President, CEO of Wellness Teladoc, Pharmacy Services Inc, Health Resources Inc and Univec Inc (UNVC). Dr. Dalton is an inductee of three Halls of Fame, has received recognition from several presidents of the United States, and is a recipient of the Senatorial-Medal of Freedom. Dr. Dalton received a Doctor of Pharmacy from West Virginia University School of Pharmacy. In addition to his extensive background in pharmaceutical field, he is a visiting professor and lectures at several schools of pharmacy throughout the United States, and former President of West Virginia University School of Pharmacy Presidential Committee.
Further information regarding the Transaction, including a detailed use of proceeds for the Financing and financial information of EuroMed, will be made available in due course. Readers are encouraged to review the listing statement which will be prepared by the Company in connection with the listing of the Company on the Canadian Securities Exchange, and which will be made available under the Company’s profile on SEDAR (www.sedar.com).
$$$ UNVC $$$
I love it when Dr. D tells us point blank at Hope Global Forums that we are going to a “one company roll-up.” UNVC/Univec Conglomerate is a risk free escape from being middle class. Don’t miss out and don’t say he didn’t tell you so.
$$$ UNVC $$$
“PPSI subsidiary of Univec Conglomerate Inc. (UNVC) will have patient assistance , access , a change is on it’s way.”- Dalton
https://www.linkedin.com/feed/update/urn:li:activity:6550158965915951104?commentUrn=urn%3Ali%3Acomment%3A%28activity%3A6550158965915951104%2C6550206489519276033%29
You are so hilarious and entertaining! We might sell after the reverse merger with LRS, but then again we might not. Waste service companies tend to pay dividends to shareholders.
$$$ ECOS $$$
I still believe our investment in ECOS will be prosperous.
Very well said TW. I live in a small town very close to Cedar Rapids. I used to have Waste Management. I switched over to a local waste service called Edwards Sanitation. They were significantly less expensive.
$$$ ECOS $$$
Too bad for them. Great investments don’t always go to the moon overnight. The UNVC price per share has come a very long way since I had bought in two years ago.
$$$ UNVC $$$
Are you saying Ecolocap and Lake Shore Recycling are dead in the water? I don’t think they are. It seems like Lake Shore Recycling is rapidly expanding and there have been recent posts on this board supporting the fact that LRS is still collecting food waste for the digester to compost.
$$$ ECOS $$$
I think that LRS has been holding their own in Illinois. they should also be able to hold their own in Illinois with the Ecolocap digester technology just as they have with their other services.
$$$ ECOS $$$
“PPSI subsidiary of Univec Conglomerate Inc. Patient assistance for those who can’t afford. Access and Change.”-Dalton
PPSI subsidiary of Univec Conglomerate Inc. Patient assistance for those who can’t afford. Access and Change.
— Dr. David Dalton (@DrDavidDalton1) June 28, 2019
PPSI is a huge dot that will translate into a rainbow leading to a huge pot of gold.
$$$ UNVC $$$
I’m still here.
$$$ ECOS $$$
Looks like verifiable proof right there buddy. I bet a video is soon to follow.
$$$ UNVC $$$
Just a friendly reminder that there are many developing events for the Univec Conglomerate;
https://sedar.com/CheckCode.do
REWARDSTREAM ENTERS INTO DEFINITIVE AGREEMENT TO ACQUIRE INTEREST IN ISRAELI CANNABIS LICENSEE
Vancouver, British Columbia, June 12, 2019 – RewardStream Solutions Inc. (TSXV: REW and Frankfurt: JL4L, WKN Number A2APX1) (the “Company”) is pleased to announce it has entered into a definitive share purchase agreement (the “Definitive Agreement”), dated effective June 11, 2019, with EuroMed Therapeutics Ltd. (“EuroMed”) and its shareholders. EuroMed is an arms’-length company, established under the laws of the Province of British Columbia, for the purpose of cultivation and exporting of medical grade cannabis produced in greenhouse facilities located in Israel. EuroMed aims to be a leading low-cost high-quality medical grade cannabis producer in Israel with a focus on both the domestic Israeli market and the emerging European cannabis market. The Definitive Agreement replaces the existing letter of intent entered into with EuroMed and dated effective April 30, 2019.
EuroMed, through its participation in a joint venture, will embark on an industrial-scale cannabis farming operation including up to a 269,098 square foot (25 dunam) cannabis designated cultivation property located 45 minutes outside of Jerusalem, Israel. The venture intends to build a 22,000 square feet greenhouse facility on the property to cultivate medical grade cannabis for the purposes of servicing the domestic medical cannabis market and exports into Europe. EuroMed will be working with leading greenhouse engineering and construction firm Eisenberg Agri Company (Israel) Limited (EACi) to design and build a state-of-the-art modular greenhouse facility with expected completion by March 2020.
Further Details Regarding the Transaction
Pursuant to the Definitive Agreement, the Company proposes to acquire all of the outstanding share capital of EuroMed (the “Transaction”). In accordance with the terms of the Transaction, the Company proposes to consolidate its outstanding share capital (the “Share Consolidation”) on a two-for-one basis, and issue 40,000,000 post-Share Consolidation common shares (the “Consideration Shares”) to the shareholders of EuroMed in exchange for all of the outstanding share capital of EuroMed.
Prior to closing of the Transaction, the Company intends to apply to list its common shares on the Canadian Securities Exchange, and voluntarily delist its shares from the TSX Venture Exchange. On closing of the Transaction, it is anticipated that the Company will change its name to “EuroMed Therapeutics Ltd.”
In connection with the Transaction, the Company anticipates issuing 4,500,000 post-Share Consolidation common shares to an arms’-length third party who assisted in introducing the Transaction to the Company.
It is a condition to completion of the Transaction that the Company undertake a non-brokered private placement (the “Financing”) of subscription receipts (each, a “Receipt”) to raise not less than $2,500,000. In order to satisfy this condition, the Company intends to offer up to 5,000,000 Receipts, at a price of $0.50 per Receipt. Proceeds of the Financing will be held in escrow pending completion of the Transaction. Immediately prior to completion of the Transaction, each Receipt will automatically be converted into one unit of the Company (each, a “Receipt Unit”). Each “Receipt Unit” will consist of one post-Share Consolidation common share of the Company, and one-half-of- one share purchase warrant (each whole warrant, a “Receipt Warrant”). Each “Receipt Warrant” will entitle the holder to acquire an additional post-Share Consolidation common share at a price of $1.00 for a period of twenty-four months from their date of issue.
All securities issued in connection with the Financing, as well as the securities issued as compensation for introducing the Transaction, will be subject to a four-month-and-one-day statutory hold period.
Completion of the Transaction remains subject to a number of conditions, including receipt of any required regulatory and third-party consents, approval of minority shareholders of the Company to the delisting of the Company’s common shares from the TSX Venture Exchange, completion of the Share Consolidation, completion of the Financing, the Canadian Securities Exchange having conditionally accepted the listing of the Company’s common shares, the TSX
Venture Exchange having consented to the voluntarily delisting of the Company’s common shares, and the satisfaction of other customary closing conditions.
The Transaction cannot close until the required approvals are obtained, and the Company’s common shares have been delisted from the TSX Venture Exchange. There can be no assurance that the Transaction will be completed as proposed or at all, or that the Company’s common shares will be listed and posted for trading on any stock exchange. Trading in the Company’s common shares is currently suspended and it is anticipated that trading will remain suspended until completion of the Transaction.
Proposed Management and Board of Directors of the Resulting Issuer
Following completion of the Transaction, it is anticipated that the board of directors of the Company will be reconstituted to consist of Patrick Morris, Geoff Balderson, David Dalton and one additional nominee to be agreed between the Company and EuroMed. Management of the Company will consist of Patrick Morris as Chief Executive Officer and Corporate Secretary, and Geoff Balderson as Chief Financial Officer. The following are brief profiles of the proposed members of management and the board of directors:
Patrick Morris: Director, Chief Executive Officer and Corporate Secretary
Mr. Morris is an entrepreneur and capital markets executive experienced in a number of industries including resource exploration, pharmaceutical cannabis, blockchain technologies, and finance. With 15 years of capital markets experience raising funds for microcap companies and executing corporate development strategies, Mr. Morris has taken numerous companies public through initial public offerings and reverse takeover transactions. Mr. Morris also co-created and co-produced Canada’s first nationally syndicated radio show about growth stock opportunities broadcast on fourteen of the top-rated news talk stations across Canada.
Geoff Balderson: Director and Chief Financial Officer
Mr. Balderson is the President of Flow Capital Corp. and Harmony Corporate Services Ltd., both private business consulting companies located in Vancouver, British Columbia. Mr. Balderson has been an officer and director of several TSX Venture Exchange listed companies over the past 12 years. Prior to that he was an investment advisor at Union Securities and Georgia Pacific Securities Corp.
David Dalton: Independent Director
Dr. Dalton is a director of AGRIMED, which owns one of the twelve licenses authorized by the Commonwealth of Pennsylvania to grow and process medical cannabis. In addition to over 45 years’ experience in the pharmaceutical world, Dr. Dalton served over 18 years as Vice President of Rite Aid, a chain of retail drug stores, and then founded and served as Chairman, President, CEO of several successful pharmaceutical and pharmaceutical related companies: Mednet, ManagedcareRx, Sivault Systems. Dr. Dalton is presently Chairman, President, CEO of Wellness Teladoc, Pharmacy Services Inc, Health Resources Inc and Univec Inc (UNVC). Dr. Dalton is an inductee of three Halls of Fame, has received recognition from several presidents of the United States, and is a recipient of the Senatorial-Medal of Freedom. Dr. Dalton received a Doctor of Pharmacy from West Virginia University School of Pharmacy. In addition to his extensive background in pharmaceutical field, he is a visiting professor and lectures at several schools of pharmacy throughout the United States, and former President of West Virginia University School of Pharmacy Presidential Committee.
Further information regarding the Transaction, including a detailed use of proceeds for the Financing and financial information of EuroMed, will be made available in due course. Readers are encouraged to review the listing statement which will be prepared by the Company in connection with the listing of the Company on the Canadian Securities Exchange, and which will be made available under the Company’s profile on SEDAR (www.sedar.com).
For more information contact:
Patrick Morris, Chief Executive Officer enermetalventures@gmail.com or 604-283-1722
Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Neither the TSX Venture Exchange, nor the Canadian Securities Exchange, has in any way passed upon the merits of the proposed Transaction and has neither approved nor disapproved the contents of this press release.
Completion of the Transaction is subject to a number of conditions, including but not limited to, the consent of the TSX Venture Exchange to the delisting of the Company, the Canadian Securities Exchange having conditionally accepted the listing of the Company, and disinterested shareholder approval. The Transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the Transaction will be completed as proposed or at all.
Investors are cautioned that, except as disclosed in the listing statement to be prepared in connection with the Transaction, any information released or received with respect to the Transaction may not be accurate or complete and should not be relied upon. Trading in the securities of the Company should be considered highly speculative.
This news release includes certain “forward-looking statements” under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements with respect to the terms and conditions of the proposed Transaction; and the proposed listing of the Company on the Canadian Securities Exchange. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward- looking statements. Such factors include, but are not limited to general business, economic, competitive, political and social uncertainties, uncertain capital markets; and delay or failure to receive board, shareholder or regulatory approvals. There can be no assurance that the Transaction will proceed on the terms contemplated above or at all and that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
$$$ UNVC $$$
“Don’t worry longs I have a rainbow of dollars for you. Let Daytrader and Flippers, market makers have the pennies Float will dry up . Univec book it. And yes This is your CEO”-Dr. David Dalton
Don’t worry longs I have a rainbow of dollars for you. Let Daytrader and Flippers, market makers have the pennies Float will dry up . Univec book it. And yes This is your CEO
— Dr. David Dalton (@DrDavidDalton1) June 21, 2019
I hope so. That what makes Oingo go Boingo. lol. Have a good weekend.
$$$ ECOS $$$
Nice find AG.
$$$ ECOS $$$
haha. I’m not sure. We will have to see.
ECOS
I would say LRS is showing that they plan to go through with the agreement that JH reminded us about.
ECOS
Food scraps can be turned into fertilizer through composting. Ensuring that most of your food waste is composted can help reduce the amount of food that goes to a landfill. Do you compost at home or at work? pic.twitter.com/oMjCKseUWV
— LRS (@LRSrecycles) June 21, 2019
Dr. D is the man! Univec will be a medical mj giant soon.
This is Dr. David Dalton Chairman, President/ CEO leading Univec Conglomerate Inc. to make changes in the Healthcare system. Providing wealth for all and support for The indigent who can’t help themselves yet and to the veterans who have given so much.
— Dr. David Dalton (@DrDavidDalton1) June 21, 2019
Wow that is great volume!
$$$ ECOS $$$
Yes sir ECOS
Thank you JHeard. ECOS
It was Jheard that reminded us of the soon to be decision day for LRS!
$$$ ECOS $$$
The reason I feel the R/S was bs is because DP sold a bunch of shares just prior to the split. Am I right or am I wrong?
I have money in this stock. I want to see it succeed. I see more success in TRTC as soon as DP moves on.
$$$ TRTC $$$
That reverse split was bs. I have heard a few speak how necessary it was. My question to that is: How has that benefited shareholders over the last 5 years? DP is not a good CEO IMO. He needs to go back to Wall St.
Google CEO Dr. David Dalton and compare his accolades to DP. You be the judge.
$$$ TRTC $$$
I agree. I am holding my shares on this stock solely on the inevitability that TRTC will get bought out for their valuable licenses to sell and cultivate.
Based on my own personal speculation though, I think TRTC is actually profitable but due to it being an all cash business with the current laws, DP is able to divert our (stockholder) profits to his wife’s boo-sums. On paper we show a loss, but in actuality DP and his wife are living high off the hog while claiming a loss on paper.
Bottom line, we need financial oversight with these companies to protect the interests of shareholders by our federal government, not El-Chapo wanna-bees like DP.
$$$ TRTC $$$
BOOM: The House of Representatives just passed a measure to block the Department of Justice and DEA from interfering in *all* state marijuana laws.
The measure goes far beyond the existing medical cannabis protection rider enacted in 2014.
https://www.forbes.com/sites/tomangell/2019/06/20/congress-votes-to-block-feds-from-enforcing-marijuana-laws-in-legal-states/